9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma

Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Pleural Malignant Mesothelioma

Estimated Enrollment: 24

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Incidence of treatment-related adverse events,  Progression-free survival assessed according to Response Evaluation Criteria for Solid Tumors version 1.1,  Overall survival assessed according to Response Evaluation Criteria for Solid Tumors version 1.1,

Interventions: Laboratory Biomarker Analysis, Palliative Radiation Therapy

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: May 31, 2020

Completion Date: May 31, 2021

Last  Posted Date: May 17, 2019

Location: M D Anderson Cancer Center, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT02959463

Was this article helpful?
Dislike 0